The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Gilder, Andrew S ^a   Natali, Letizia ^a   Van Dyk, Danielle M ^a   Zalfa, Cristina ^a   Banki, Michael A ^a   Pizzo, Donald P ^a   Wang, Huawei ^a   Klemke, Richard L ^a   Mantuano, Elisabetta ^a,b   Gonias, Steven L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLAUR PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTOME; UROKINASE RECEPTOR;

ANIMAL; BRAIN TUMOR; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; COHORT ANALYSIS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; MESENCHYMAL STEM CELL; MORTALITY; MOUSE; PHYSIOLOGY; SURVIVAL ANALYSIS; TISSUE MICROARRAY; TUMOR CELL CULTURE;

ANIMALS; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COHORT STUDIES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MESENCHYMAL STEM CELLS; MICE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 85042108401     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-21358-1     Document Type: Article

References (65)

1. Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell. 139, 871-890 (2009).
2. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7, 131-142 (2006).
3. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133, 704-715 (2008).
4. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance, an emerging axis of evil in the war on cancer. Oncogene. 29, 4741-4751 (2010).
5. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 339, 580-584 (2013).
6. Blasi, F., Vassalli, J. D. & Dano, K. Urokinase-type plasminogen activator, proenzyme, receptor, and inhibitors. J Cell Biol. 104, 801-804 (1987).
7. Andreasen, P. A., Kjoller, L., Christensen, L. & Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis, a review. Int J Cancer. 72, 1-22 (1997).
8. Ploug, M., Behrendt, N., Lober, D. & Dano, K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost. 17, 183-193 (1991).
9. Blasi, F. & Carmeliet, P. uPAR, a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 3, 932-943 (2002).
10. Jo, M. et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem. 280, 17449-17457 (2005).
11. Smith, H. W. & Marshall, C. J. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 11, 23-36 (2010).
12. Lester, R. D., Jo, M., Montel, V., Takimoto, S. & Gonias, S. L. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 178, 425-436 (2007).
13. Jo, M. et al. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 284, 22825-22833 (2009).
14. Nguyen, D. H., Hussaini, I. M. & Gonias, S. L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem. 273, 5802-8507 (1998).
15. Webb, D. J., Nguyen, D. H. & Gonias, S. L. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci. 113, 123-134 (2000).
16. Alfano, D. et al. The urokinase plasminogen activator and its receptor, role in cell growth and apoptosis. Thromb Haemost. 93, 205-211 (2005).
17. Ma, Z., Webb, D. J., Jo, M. & Gonias, S. L. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci. 114, 3387-3396 (2001).
18. Alfano, D., Iaccarino, I. & Stoppelli, M. P. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem. 281, 17758-17767 (2006).
19. Jo, M. et al. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res. 70, 8948-8958 (2010).
20. Jo, M., Takimoto, S., Montel, V. & Gonias, S. L. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am J Pathol. 175, 190-200 (2009).
21. Pirazzoli, V., Ferraris, G. M. & Sidenius, N. Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth. Blood. 121, 2316-2323 (2013).
22. Eastman, B. M., Jo, M., Webb, D. L., Takimoto, S. & Gonias, S. L. A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen. Cell Signal. 24, 1847-1855 (2012).
23. Omuro, A. & DeAngelis, L. M. Glioblastoma and other malignant gliomas, a clinical review. JAMA. 310, 1842-1850 (2013).
24. Furnari, F. B. et al. Malignant astrocytic glioma, genetics, biology, and paths to treatment. Genes Dev. 21, 2683-2710 (2007).
25. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455, 1061-1068 (2008).
26. Dunn, G. P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756-784 (2012).
27. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell. 155, 462-477 (2013).
28. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17, 98-110 (2010).
29. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9, 157-173 (2006).
30. Sullivan, J. P. et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 4, 1299-1309 (2014).
31. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344, 1396-1401 (2014).
32. Hu, J. et al. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci USA 108, 15984-15989 (2011).
33. Hu, J. et al. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. 34, 1-11 (2014).
34. Wykosky, J. et al. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 75, 394-404 (2015).
35. Gunther, H. S. et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 27, 2897-2909 (2008).
36. Laks, D. R. et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 27, 980-987 (2009).
37. Chen, R. et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 17, 362-375 (2010).
38. Yamamoto, M. et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 54, 3656-3661 (1994).
39. Salajegheh, M., Rudnicki, A. & Smith, T. W. Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. Appl Immunohistochem Mol Morphol. 13, 184-189 (2005).
40. Ceccarelli, M. et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 164, 550-563 (2016).
41. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq, a revolutionary tool for transcriptomics. Nat Rev Genet. 10, 57-63 (2009).
42. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 17, 510-522 (2010).
43. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483, 479-483 (2012).
44. Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021 (2004).
45. Weiswald, L. B., Bellet, D. & Dangles-Marie, V. Spherical cancer models in tumor biology. Neoplasia 17, 1-15 (2015).
46. Mao, P. et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 110, 8644-8649 (2013).
47. Brown, D. V. et al. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget. 6, 6267-6280 (2015).
48. Lottaz, C. et al. Transcriptional profiles of CD133+ and CD133? glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res. 70, 2030-2040 (2010).
49. Yu, S. C. et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett. 265, 124-134 (2008).
50. Heimberger, A. B. et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 11, 1462-1466 (2005).
51. Sugawa, N., Ekstrand, A. J., James, C. D. & Collins, V. P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87, 8602-8606 (1990).
52. Nishikawa, R. et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91, 7727-7731 (1994).
53. Gilder, A. S. et al. Pertussis Toxin Is a Robust and Selective Inhibitor of High Grade Glioma Cell Migration and Invasion. PLoS One. 11, e0168418 (2016).
54. Mazar, A. P. Urokinase plasminogen activator receptor choreographs multiple ligand interactions, implications for tumor progression and therapy. Clin Cancer Res. 14, 5649-5655 (2008).
55. Gonias, S. L. & Hu, J. Urokinase receptor and resistance to targeted anticancer agents. Front Pharmacol 6, 154 (2015).
56. Solberg, H., Ploug, M., Hoyer-Hansen, G., Nielsen, B. S. & Lund, L. R. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem. 49, 237-246 (2001).
57. Merino, P., Diaz, A. & Yepes, M. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain. Receptors Clin Investig. 4, e1552 (2017).
58. Graham, C. H., Fitzpatrick, T. E. & McCrae, K. R. Hypoxia stimulates urokinase receptor expression through a heme proteindependent pathway. Blood. 91, 3300-3307 (1998).
59. Bugge, T. H. et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem. 270, 16886-16894 (1995).
60. Dano, K. et al. Plasminogen activation and cancer. Thromb Haemost. 93, 676-681 (2005).
61. Frisch, S. M. & Ruoslahti, E. Integrins and anoikis. Curr Opin Cell Biol. 9, 701-706 (1997).
62. Inda, M. M. et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 24, 1731-1745 (2010).
63. Zanca, C. et al. Glioblastoma cellular cross-talk converges on NF-kappaB to attenuate EGFR inhibitor sensitivity. Genes Dev. https:// doi. org/10. 1101/gad. 300079. 117 (2017).
64. Gilder, A. S. et al. Soluble urokinase receptor is released selectively by glioblastoma cells that express epidermal growth factor receptor variant III and promotes tumor cell migration and invasion. J Biol Chem. 290, 14798-14809 (2015).
65. Jo, M., Thomas, K. S., O'Donnell, D. M. & Gonias, S. L. Epidermal growth factor receptor-dependent and-independent cellsignaling pathways originating from the urokinase receptor. J Biol Chem. 278, 1642-1646 (2003).